Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study

JAMA Psychiatry

Volumn 70, Issue 10, 2013, Pages 1057-1066

  De La Fuente Sandoval, Camilo ^a   León Ortiz, Pablo ^a   Azcárraga, Mariana ^a   Stephano, Sylvana ^a   Favila, Rafael ^b   Díaz Galvis, Leonardo ^c   Alvarado Alanis, Patricia ^a   Ramírez Bermúdez, Jesús ^a   Graff Guerrero, Ariel ^d,e  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b GE HEALTHCARE   (United Kingdom)

^c Latin America Medical Affairs   (Mexico)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; ASPARTIC ACID; CANNABIS; CREATINE PHOSPHATE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GUANIDINOACETIC ACID; LACTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; RISPERIDONE; TAURINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ASSOCIATIVE STRIATUM; BRAIN REGION; BRIEF PSYCHOTIC DISORDER; CEREBELLUM CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HANDEDNESS; HUMAN; INFERIOR CEREBELLAR PEDUNCLE; LONGITUDINAL STUDY; MALE; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SMOKING; TREATMENT DURATION; ADOLESCENT; CONTROLLED CLINICAL TRIAL; CORPUS STRIATUM; DRUG EFFECTS; FUNCTIONAL NEUROIMAGING; METABOLISM; MIDDLE AGED; PSYCHOTIC DISORDERS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CEREBELLAR CORTEX; CORPUS STRIATUM; FEMALE; FUNCTIONAL NEUROIMAGING; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 84885218013     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.289     Document Type: Article

References (53)

1. Belforte JE, Zsiros V, Sklar ER, et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci. 2010;13(1):76-83.
2. Sharp FR, Tomitaka M, BernaudinM, Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci. 2001;24(6): 330-334.
3. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52(12):998-1007.
4. Bartha R,Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54(10):959-965.
5. Théberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159(11):1944-1946.
6. Bustillo JR, Rowland LM, Mullins P, et al. 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010;15(6):629-636.
7. Goto N, Yoshimura R, Kakeda S, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat. 2012;8:119-122.
8. Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69(5):449-459.
9. Théberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 2003;160(12):2231-2233.
10. ReidMA, Stoeckel LE, White DM, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2010;68(7):625-633.
11. Bustillo JR, Chen H, Gasparovic C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 tesla. Biol Psychiatry. 2011;69(1):19-27.
12. Rowland LM, Kontson K,West J, et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia [published online October 18, 2012]. Schizophr Bull. doi:10.1093/schbul/sbs092.
13. de la Fuente-Sandoval C, León-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011;36(9):1781-1791.
14. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260-264.
15. Jiru F, Skoch A, Klose U, GroddW, Hajek M. Error images for spectroscopic imaging by LCModel using Cramer-Rao bounds. MAGMA. 2006;19(1):1-14.
16. Bustillo JR, Rowland LM, Jung R, et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology. 2008;33(10):2456-2466.
17. Cook R,Weisberg S. Residuals and Influence in Regression. New York, NY: Chapman & Hall; 1982.
18. Egerton A, Brugger S, Raffin M, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37(11):2515-2521.
19. Ongür D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64(8):718-726.
20. Ota M, Ishikawa M, Sato N, et al. Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation. Acta Psychiatr Scand. 2012;126(1):72-78.
21. de la Fuente-Sandoval C, Léon-Ortiz P, Azcárraga M, Favila R, Stephano S, Graff-Guerrero A. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol. 2013;16(2):471-475.
22. Mawlawi O, Martinez D, SlifsteinM, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography, I: accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21(9):1034-1057.
23. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13-20.
24. Kegeles LS, Abi-Dargham A, FrankleWG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67(3):231-239.
25. Graff-Guerrero A, Willeit M, Ginovart N, et al. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp. 2008;29(4):400-410.
26. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45(1):71-76.
27. Carter CS, MacDonald AWIII, Ross LL, Stenger VA. Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study. Am J Psychiatry. 2001;158(9):1423-1428.
28. Seidman LJ, Giuliano AJ,Meyer EC, et al; North American Prodrome Longitudinal Study (NAPLS) Group. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67(6):578-588.
29. Camps M, Cortés R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience. 1989;28(2):275-290.
30. Middleton FA, Strick PL. Cerebellar projections to the prefrontal cortex of the primate. J Neurosci. 2001;21(2):700-712.
31. Segovia G, Del Arco A, Mora F. Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: amicrodialysis study. J Neurochem. 1997;69(4):1476-1483.
32. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000;48(7):627-640.
33. Breier A, Adler CM,Weisenfeld N, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse. 1998;29(2):142-147.
34. Aalto S, Ihalainen J, Hirvonen J, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl). 2005;182(3):375-383.
35. Smith GS, Schloesser R, Brodie JD, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology. 1998;18(1):18-25.
36. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005;162(2):394-396.
37. Stone JM, Dietrich C, Edden R, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012;17(7):664-665.
38. Steen RG, Hamer RM, Lieberman JA. Measurement of brainmetabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology. 2005;30(11):1949-1962.
39. Barker PB. N-acetyl aspartate: a neuronal marker? Ann Neurol. 2001;49(4):423-424.
40. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport. 1996;7(8):1397-1400.
41. Ariyannur PS, Madhavarao CN, Namboodiri AM. N-acetylaspartate synthesis in the brain: mitochondria vs. microsomes. Brain Res. 2008;1227:34-41.
42. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res. 1994;13(3):195-207.
43. Auer DP,WilkeM, Grabner A, Heidenreich JO, Bronisch T,Wetter TC. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res. 2001;52(1-2):87-99.
44. Bustillo JR, Rowland LM, Lauriello J, et al. High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia. Am J Psychiatry. 2002;159(1):130-133.
45. Stanley JA, Kipp H, Greisenegger E, et al. Regionally specific alterations in membrane phospholipids in children with ADHD: an in vivo 31P spectroscopy study. Psychiatry Res. 2006;148(2-3):217-221.
46. Wood SJ, Berger GE,Wellard RM, et al. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis. Schizophr Res. 2008;102(1-3):163-170.
47. Rothermundt M, Ohrmann P, Abel S, et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):361-364.
48. Chua SE, Cheung C, Cheung V, et al. Cerebral grey, white matter and CSF in never-medicated, first-episode schizophrenia. Schizophr Res. 2007;89(1-3):12-21.
49. Clementi V, Tonon C, Lodi R, Malucelli E, Barbiroli B, Iotti S. Assessment of glutamate and glutamine contribution to in vivo N-acetylaspartate quantification in human brain by 1H-magnetic resonance spectroscopy. Magn Reson Med. 2005;54(6):1333-1339.
50. de la Fuente-Sandoval C, Favila R, Alvarado P, et al. Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study [in Spanish]. Gac Med Mex. 2009;145(2):109-113.
51. KeshavanMS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley JA. Striatalmetabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a 1H spectroscopy study. Schizophr Res. 2009;115(1):88-93.
52. Seese RR, O'Neill J, Hudkins M, et al. Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia. Schizophr Res. 2011;133(1-3):82-90.
53. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K. Brainmetabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry. 2007;62(12):1396-1404.